Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis

Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi
Tomoyuki OtsukaShuichi Tsuruoka

Abstract

Sustained erythropoiesis-stimulating agents (ESAs) have recently been identified as the standard therapeutic agent for anemia in patients undergoing peritoneal dialysis (PD). However, few reports have compared pain between various types of sustained ESAs or between administration routes. Furthermore, the change ratio of the dose of sustained ESAs reportedly ranges from 0.8 to 1.3. In the present study, to compare darbepoetin alfa and epoetin beta pegol (a continuous erythropoietin receptor activator [CERA]), we examined the dolorific differences between administration routes and the effect on anemia by using a chjange ratio of 0.8 with darbepoetin alfa in patients with renal anemia undergoing PD. We randomly assigned 20 patients with stable hemoglobin levels undergoing PD to either a darbepoetin alfa therapy group or a CERA therapy group. Based on a previous report, the change ratio of the CERA group from CERA to darbepoetin alfa therapy was assumed to be 0.8, and therapy was crossed-over to darbepoetin alfa again 2 months later. The dolorific evaluation (pain measurement) used both a face scale and a visual analogue scale. We compared the agents as well as administration routes with respect to pain. We also measured variables ...Continue Reading

References

Jul 8, 2005·Journal of Clinical Nursing·Amelia Williamson, Barbara Hoggart
Jul 1, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Bernard CanaudUNKNOWN STRIATA Study Investigators
Jun 5, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Fernando CarreraUNKNOWN PATRONUS Investigators
Jun 24, 2011·Kidney International·Oluwatoyin F Bamgbola
Jul 9, 2011·Current Opinion in Nephrology and Hypertension·Holger SchmidStephan R Lederer
Nov 3, 2011·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Nicholas M SelbyMaarten W Taal
Feb 27, 2013·Nature Reviews. Nephrology·Walter H Hörl
Apr 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
Jul 16, 2014·Expert Review of Hematology·Lucia Del Vecchio, Francesco Locatelli

❮ Previous
Next ❯

Citations

Aug 7, 2017·The Cochrane Database of Systematic Reviews·Valeria M SaglimbeneGiovanni Fm Strippoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Yuki MorikamiMakoto Sakai
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
C A JohnsonM R Kosorok
Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Yuki MorikamiMakoto Sakai
International Urology and Nephrology
Kleyton BastosRicardo Correa-Rotter
© 2021 Meta ULC. All rights reserved